The present paper aims to investigate the clinical distribution of Candida tropicalis (C. tropicalis) and its sensitivity to antifungal drugs. C. tropicalis isolates were separated from clinical specimens, and defined by ID 32 C identification system of BioMerieux. BIO-KONT fungal rapid color-development method was applied to test susceptibility to antifungal drugs in vitro. From January 2010 to December 2011 a total of 110 C. tropicalis isolates were separated, accounting for 14.34 % of all isolates of Candida. The infection of C. tropicalis was common in respiratory diseases, urinary tract diseases and diabetes. Over 90.00% of the isolates were sensitive to nystatin, amphotericin B and flucytosine. Sensitivities to azoles were between 44.55%-90.00%. Only 8.18% of the isolates were sensitive to terbinafine